We are looking for consultants who have good understanding of the biopharma sector.
User angelinaarch26. User angelinaarch26. Angelinaarch26. Angelinaarch26. GwrBook - PageRank 4 DoFollow Social Bookmarking Site. BiopharmaVantage which is Oxford based healthcare consultancy specializing in Strategy Consulting, Competitive Intelligence, Valuation and Due Diligence BiopharmaVantage offers a full range of licensing, partnering and transactions services for clients seeking to internalise and externalise assets.
We assist healthcare clients with competitive intelligence, medical congress coverage, strategic analysis, competitive landscape and due diligence. BiopharmaVantage is a specialty cosultancy that partners with healthcare clients to help them take optimal decisions. Valuation is central to a multitude of decision-making processes; it is one of the most frequently applied tools in a wide range of business scenarios. Few business practices have had as rapid an uptake as competitive intelligence (CI).
Angelinaarch26. EC Social Bookmarking. Angelinaarch26. Competitive Intelligence in the Pharma/Biotech vs other sectors – Biopharmavantage. Few business practices have had as rapid an uptake as competitive intelligence (CI).
Not only the pharma industry but also other industries have witnessed this rapid uptake. Over the years, the applications of CI have grown and matured, and competitive intelligence has gone from a ‘nice to have’ to a ‘must have’ function in a multitude of organizations. Some organizations have been early adopters of the practice, most are ‘early/late majority’ adopters and some have yet to leverage the practice to their benefit. The Importance of Appropriate Addressable Market – Biopharmavantage. Addressing the appropriate market is often one of the key success factors in due diligence, new product planning, opportunity assessment and business plans.
Prima facie, everybody likes large market size and significant unmet needs. However, it is vital to focus on the market or segment where the asset will compete in, at least in the first instance. Case-in-point: Significant excitement about a first-in-class biologic for asthma treatment. While there is high unmet need and asthma market size is large, the first-in-class biologic therapy is unlikely to be the first-line treatment for asthma, primarily for two reasons- a) the medical treatment algorithm might call for much simpler intervention as the first-line of treatment b) price watch dogs may stipulate cost-effective options as the first-line treatment. Similarly, a novel cancer therapy while it may be groundbreaking but may not become the first line treatment.
Source: Small Pharma/Biotech Benefit by Focusing Beyond the Usual Suspects For Licensing And Partnering – Biopharmavantage. Licensing and partnering are central to the growth of pharmaceutical companies, and are particularly critical for emerging companies.
On a spectrum that ranges from developing assets in-house to outright asset acquisition, licensing and partnering occupy an intermediate position, and offer the benefit of risk-reward sharing. Majority of small pharma/biotech companies have traditionally been focusing on large pharma companies (usual suspects) in order to commercialize their assets. Evidence suggests that: The usual suspects are limited in numberThe usual suspects engage in a relatively small volume of dealsThe usual suspects’ asset attribute requirements for licensing and partnering are relatively very high Consequently, the probability of forging a successful deal with usual suspects is seldom high.
Source: Like this: Like Loading... Evaluating Potential Opportunities in Pharmaceutical and Biotechnology Sector – Biopharmavantage. While looking for potential assets and partners, it’s essential to conduct proper life sciences due diligence – investigate asset, company, market position, recent deals, strategy and financials.
The research should not only look at the history of the asset/partner but also it should incorporate forward looking intent, strategy, pipeline and the strength and weakness from your point of view as well as from the lens of other key opinion leaders (KOLs). BiopharmaVantage conducts rigorous research and due diligence. The company collectshigh quality intelligence and insights from a wide range of sources covering both primary and secondary resources.
Best Vendors for Competitive Intelligence services – Biopharmavantage. What is Competitive Intelligence?
Acc to Wikipedia, Competitive intelligence is the action of defining, gathering, analyzing, and distributing intelligence about products, customers, competitors, and any aspect of the environment needed to support executives and managers making strategic decisions for an organization. Here Are the Best Websites for Gathering Competitive Intelligence BiopharmaVantage provides up to date competitive intelligence. The company takes pride in providing exceptional quality primary and secondary intelligence enabling clients take informed and smarter decisions. ProQuest is committed to empowering researchers and librarians around the world. Hoover’s Inc., a subsidiary of The Dun & Bradstreet Corporation, offers proprietary business information through our online platform and integrated workflow solutions.
Like this: Like Loading... Strategy and Competitive Analysis – Biopharmavantage. Market sizing, Due Diligence, Opportunity assessment - Market sizing, Due Diligence, Opportunity assessment - Competitve Intelligence. Competitve Intelligence. HealthCare Advice: Evaluating Potential Opportunities in Pharmaceutical and Biotechnology Sector. HealthCare Advice: Best Vendors for Competitive Intelligence Services. Empowering pharmaceutical, biotechnology, diagnostics companies and Healthcare Investors - Healthcare and Life Sciences Strategy, Competitive Intelligence and Due Diligence. Empowering pharmaceutical, biotechnology, diagnostics companies and Healthcare Investors - Healthcare and Life Sciences Strategy, Competitive Intelligence and Due Diligence. Empowering pharmaceutical, biotechnology, diagnostics companies and Healthcare Investors - Healthcare and Life Sciences Strategy, Competitive Intelligence and Due Diligence.
Competitive Intelligence BiopharmaVantage provides up to date competitive intelligence.
We take pride in providing high quality primary and secondary intelligence enabling our client take informed and smarter decisions. Key features of our intelligence gathering programs are:Bespoke to meet your specific needsCover your needs across the life cycle of assets – ranging from preclinical assets to products that are approaching loss of exclusivitySpan multiple therapy areas, functional areas and geographiesEngagement mode includes ad hoc projects, monitoring programs, retainer programs and medical congress coverageThe output is designed in such a manner that it is easy for the decision makers to assimilate key insights Strategy and Competitive Analysis Right decisions are underpinned by robust analyses. Due Diligence Managing an optimum portfolio of assets is vital, not only to maintain the current position in the market place but also to fuel growth of the franchise/company in the long run.
For pharmaceutical, biotechnology, diagnostics companies and Healthcare Investors - Healthcare and Life Sciences Strategy, Competitive Intelligence and Due Diligence. Healthcare and Life Sciences Strategy, Competitive Intelligence and Due Diligence - Empowering pharmaceutical, biotechnology, diagnostics companies and Healthcare Investors.